SASHA LATYPOVA CALLS FOR EMA STAFF TO DO THE RIGHT THING

Hedley interviews Sasha, a pharma insider and whistleblower

WHO IS SASHA LATYPOVA?

Sasha Latypova built two businesses in pharma over 20+ years, supporting companies like Pfizer and J&J in running clinical trials. She sold both businesses, and in 2014, retired to spend more time on the ski slopes.

Fast-forward to 2020, and SARS-CoV-2 drags her back into an industry she thought she had waved goodbye to forever. Thank heavens she returned, as this chilling interview demonstrates.

TOXIC BATCHES WERE FIRST ON THE LIST

It began with analysis of data recorded in the US Vaccine Adverse Event Reporting System (VAERS). Analysis was pointing towards some batches of injections that were far more toxic than the others. Sasha began collaborating with the analysts in the PJH Law team, with stunning results you can hear about in the interview.

This is where I happened upon Sasha’s work.

REGULATORY EVALUATION RAISES GIANT RED FLAG

Drilling down further into the global regulatory evaluation of emergency and conditional use applications, she was horrified at what she learnt—a never before developed gene therapy drug approved by all agencies, at exactly the same time, at a pre-agreed date.

Committing to any date of approval has always been an absolute ‘no-no’ for regulatory bodies, as unexpected findings could crop up at any time. Watch the video for the detail.

ASKING EUROPEAN MEDICINES AGENCY (EMA) STAFF TO DO THE RIGHT THING

More digging from Sasha turns up leaked EMA emails and details of the staff involved—about 140 staff in total.

The next step is to call on those staff, highly trained in what they do across multiple disciplines, to do the right thing. Hiding behind ‘they told me to do it’ is no defense in matters like this, and who would argue with that?

They will have the opportunity to volunteer evidence as part of ongoing investigations.

For the whole story, from the horse’s mouth (sorry Sasha, metaphorical of course!), not the media jockey’s, watch the interview here.